Tenon Medical (NASDAQ:TNON) Issues Quarterly Earnings Results

Tenon Medical (NASDAQ:TNON) posted its quarterly earnings data on Tuesday. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.01), Zacks reports. Tenon Medical had a negative net margin of 318.36% and a negative return on equity of 409.16%.

Here are the key takeaways from Tenon Medical’s conference call:

• Tenon reported Q1 revenue of $1.4 million, nearly doubling year over year, with gross margin expanding to 68.5% from 44.5% last year. Management said these were the best first-quarter revenue and gross profit results in company history.
• Growth was driven by higher Catamaran procedure volumes and the first full quarter of meaningful SImmetry+ contribution after the SiVantage acquisition. The company said physician training and adoption remained strong, with 21 physicians trained during the quarter.
• The company closed a $4.3 million senior convertible note financing in March, which it said extends runway and supports ongoing investment in commercialization, product launches, and clinical programs. Cash and equivalents ended the quarter at $4.6 million, up from $3.8 million at year-end 2025.
• Management highlighted an expanding intellectual property portfolio, now at 29 U.S. patents and 9 international patents granted with 31 applications pending. It also pointed to multiple notices of allowance expected to convert into additional patents later in 2026.
• Tenon outlined several future growth catalysts, including a full SImmetry+ launch, additional platform enhancements in the second half of 2026, and a new approach to the sacro-pelvic anatomy targeted for alpha in Q4 2026. Management expects these launches, along with continued physician training, to support growth into 2027 and beyond.

Tenon Medical Stock Performance

Shares of NASDAQ:TNON traded up $0.02 on Tuesday, hitting $0.81. 222,691 shares of the company were exchanged, compared to its average volume of 730,445. The company’s 50 day moving average price is $0.78 and its two-hundred day moving average price is $0.93. Tenon Medical has a one year low of $0.64 and a one year high of $2.48. The firm has a market capitalization of $9.20 million, a price-to-earnings ratio of -0.41 and a beta of 1.28.

Institutional Trading of Tenon Medical

Several institutional investors have recently made changes to their positions in TNON. Jane Street Group LLC acquired a new stake in shares of Tenon Medical during the 1st quarter valued at about $29,000. Geode Capital Management LLC boosted its position in shares of Tenon Medical by 34.6% during the 4th quarter. Geode Capital Management LLC now owns 66,640 shares of the company’s stock valued at $63,000 after acquiring an additional 17,137 shares in the last quarter. Finally, DRW Securities LLC acquired a new stake in shares of Tenon Medical during the 4th quarter valued at about $98,000. 22.74% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Tenon Medical in a research report on Monday, April 20th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Tenon Medical currently has an average rating of “Hold”.

Tenon Medical Company Profile

Tenon Medical, Inc is a development-stage medical device company focused on the research, development and commercialization of next-generation surgical biologic adhesives and sealants. The company’s proprietary platform is designed to create tissue-compatible adhesives that can serve as alternatives or complements to traditional sutures and staples, with the goal of improving surgical efficiency, reducing postoperative complications and enhancing patient outcomes.

Tenon Medical’s product pipeline centers on protein-based polymer formulations that cross-link in situ to form a flexible, yet durable, bond with native tissue.